{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:57:09Z","timestamp":1764403029443,"version":"3.37.3"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN2722010000291","HHSN27200004"],"award-info":[{"award-number":["HHSN2722010000291","HHSN27200004"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK6BX005232"],"award-info":[{"award-number":["IK6BX005232"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although atovaquone is effective in treating and preventing Pneumocystis pneumonia (PCP), its use is limited by nonlinear absorption and adverse events. The current study was undertaken to examine the activity of encochleated atovaquone (eATQ), a novel lipid-crystal nanoparticle formulation, in a mouse model of PCP. eATQ 100\u2013200 mg was superior to commercially available atovaquone at 14 days in decreasing total Pneumocystis nuclei and asci. eATQ plus anidulafungin reduced nuclei significantly better than commercial atovaquone plus anidulafungin. eATQ is a novel formulation of atovaquone that warrants further evaluation for treatment and prevention of PCP.<\/jats:p>","DOI":"10.1093\/infdis\/jiaa731","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:20:29Z","timestamp":1606263629000},"page":"326-331","source":"Crossref","is-referenced-by-count":1,"title":["A Novel Encochleated Formulation Improves Atovaquone Activity in a Murine Model of <i>Pneumocystis<\/i> Pneumonia"],"prefix":"10.1093","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6621-2784","authenticated-orcid":false,"given":"Melanie T","family":"Cushion","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA"},{"name":"Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parag","family":"Kumar","sequence":"additional","affiliation":[{"name":"Clinical Pharmacokinetics Research Unit, Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruying","family":"Lu","sequence":"additional","affiliation":[{"name":"Matinas BioPharma Inc, Bedminster, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Ashbaugh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian W","family":"Adeojo","sequence":"additional","affiliation":[{"name":"Clinical Pharmacokinetics Research Unit, Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Alfaro","sequence":"additional","affiliation":[{"name":"Clinical Pharmacokinetics Research Unit, Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Mannino","sequence":"additional","affiliation":[{"name":"Matinas BioPharma Inc, Bedminster, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund","family":"Tramont","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5191-9880","authenticated-orcid":false,"given":"Joseph A","family":"Kovacs","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"author":"Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents","key":"2021071506151617600_CIT0001"},{"key":"2021071506151617600_CIT0002","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021071506151617600_CIT0003","first-page":"267","article-title":"Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation: ciprofloxacin versus co-trimoxazole","volume":"15","author":"Imrie","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"2021071506151617600_CIT0004","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJM199812243392604","article-title":"Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group","volume":"339","author":"El-Sadr","year":"1998","journal-title":"N Engl J Med"},{"key":"2021071506151617600_CIT0005","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1086\/314893","article-title":"Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides","volume":"180","author":"Chan","year":"1999","journal-title":"J Infect Dis"},{"key":"2021071506151617600_CIT0006","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1592\/phco.19.13.1050.31598","article-title":"Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study","volume":"19","author":"Falloon","year":"1999","journal-title":"Pharmacotherapy"},{"key":"2021071506151617600_CIT0007","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJM199305273282103","article-title":"Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS","volume":"328","author":"Hughes","year":"1993","journal-title":"N Engl J Med"},{"key":"2021071506151617600_CIT0008","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/clinids\/24.3.422","article-title":"Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone\/Toxoplasmic Encephalitis Study Group","volume":"24","author":"Torres","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2021071506151617600_CIT0009","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1086\/339551","article-title":"Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237\/ANRS 039 Study. AIDS Clinical Trials Group 237\/Agence Nationale de Recherche sur le SIDA, Essai 039","volume":"34","author":"Chirgwin","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2021071506151617600_CIT0010","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3109\/08982100009031116","article-title":"Cochleates: new lipid-based drug delivery system","volume":"10","author":"Zarif","year":"2000","journal-title":"J Liposome Res"},{"key":"2021071506151617600_CIT0011","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/AAC.44.9.2356-2360.2000","article-title":"Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis","volume":"44","author":"Santangelo","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2021071506151617600_CIT0012","article-title":"Efficacy of oral encochleated amphotericin B in a mouse model of cryptococcal meningoencephalitis","volume":"10:e00724-19","author":"Lu","year":"2019","journal-title":"mBio"},{"key":"2021071506151617600_CIT0013","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1165\/ajrcmb\/5.2.186","article-title":"Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T lymphocytes","volume":"5","author":"Beck","year":"1991","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2021071506151617600_CIT0014","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/infdis\/jiw249","article-title":"\u03b2-glucans are masked but contribute to pulmonary inflammation during Pneumocystis pneumonia","volume":"214","author":"Kutty","year":"2016","journal-title":"J Infect Dis"},{"key":"2021071506151617600_CIT0015","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1128\/IAI.01181-12","article-title":"Characterization of a distinct host response profile to Pneumocystis murina asci during clearance of pneumocystis pneumonia","volume":"81","author":"Linke","year":"2013","journal-title":"Infect Immun"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa731\/36094215\/jiaa731.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/224\/2\/326\/38984195\/jiaa731.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/224\/2\/326\/38984195\/jiaa731.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T06:16:51Z","timestamp":1626329811000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/224\/2\/326\/6007512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,27]]},"published-print":{"date-parts":[[2021,7,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa731","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2021,7,15]]},"published":{"date-parts":[[2020,11,27]]}}}